DHDaphne A. Haas-Kogan

Daphne A. Haas-Kogan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daphne A. Haas-Kogan has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Toward an Improved Understanding of the Ionizing Radiation Induced DNA Damage/Response Networks in Human Malignancies

    by Daphne A. Haas-Kogan, David R. Raleigh, Adam Paul Dicker

    Several molecular aberrations in glioblastoma have been shown to have prognostic significance, and investigations of targeted therapies for glioma patients are ongoing. Here, Wachsberger and colleagues demonstrate that overexpression of a constitutively active form of the epidermal growth factor receptor (EGFR) found in some glioblastomas sensitizes cells to both multimodal cytotoxic therapy and cetuximab (1). The data further indicate that EGFR mutation may predispose gliomas to defective homologous recombination repair (HRR). These findings are relevant to future clinical trials, and suggest that targeted agents may achieve the greatest benefit in glioma patients who have been stratified according to molecular markers. DNA damage triggers a signaling cascade that affects expression, subcellular localization, and activity of mediators; the strength and nature of molecular interactions; and chromatin structure. Ongoing discovery of novel effectors has amplified understanding of the complex network that mediates the DNA damage response (DDR). Recent evidence demonstrates that genotoxic stress regulates expression of distinct microRNAs (miRNA), some of which have been shown to directly influence expression of DDR effectors including ATM, DNA-PKcs, and BRCA1. The links between miRNAs and the DDR are summarized here by Wright and colleagues, as are the implications of future investigation into this emerging field (2). Disparate sensitivity to the cytotoxic effects of radiation mediates selective tumor cell killing with relative preservation of normal tissues. Significant effort has been dedicated to understanding the mechanisms underlying differential radiosensitivity with the ultimate goal of enhancing the therapeutic ratio of ionizing radiation. Homologous recombinational repair is among the primary pathways utilized by cells to process otherwise lethal DNA damage, and is therefore a promising target to improve the efficacy of radiation therapy. The major pathways of double-strand break repair are summarized here by Mladenov and colleagues, as are potential targets for radiosensitizing cancer cells (3). Every year, more than 700 childhood cancer survivors will join the 300,000 individuals in the United States who have survived their cancer diagnoses, but will struggle with the consequences of the treatments that cured them. Twenty-five years after the first cancer diagnosis, the death rate due to subsequent malignancies exceeds that due to all other causes. Technological advances have transformed the delivery of radiation, resulting in more conformal radiation plans. We must investigate whether the benefit of decreasing acute side effects comes at a cost of lower-dose radiation distributed throughout the child’s body that may increase the risk of fatal radiation-induced cancers. Braunstein and colleagues highlight such investigations into the current state of epidemiologic modeling and radiotherapy delivery data and their impacts on patient care (4). A comprehensive, cutting edge approach to gliomas requires first a critical understanding of the molecular underpinnings of glioma pathogenesis and response to therapy. Advances in molecular, genetic, and biochemical technologies have provided unprecedented insight into glioma biology and these are reviewed herein by Dasgupta and colleagues (5). Targeted therapeutics are available for many implicated pathways; however, follow up biological studies defining the appropriate, most effective agents for each alteration are lacking. Clinical studies must be designed that collect and harness molecular data within prospective trials, in order to generate pre-clinical and clinical data that will determine the best combination of agents for each molecular subtype. Rivera and colleagues explore the mechanisms underlying radiation resistance in GBM initiating cells (GICs) that are critical to enhanced therapeutic efficacy against neural progenitor cells (NPCs) (6) The importance of this approach is highlighted by several recent reports of improved glioma control and clinical outcome when aggressive therapy and higher doses of radiation are administered to the adult human subventricular zone, which constitutes the largest area of neurogenesis and houses the greatest concentration of NPCs. Such approaches are now possible with our modern arsenal of sophisticated dose delivery technology, with which we can modulate the dose to substructures of the brain. Recent clinical trials have demonstrated high rates of long-term local control and survival from early stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT). Compared to conventionally fractionated radiation regimens, the success of SBRT for NSCLC suggests that hypofractionated irradiation may induce distinct molecular pathways to enhance cell killing. Using two genetically engineered mouse models of NSCLC, Perez and colleagues demonstrate superior tumor control with hypofractionated radiation. The cellular response to SBRT is incompletely understood, but the genetic reagents described here will be useful to elucidating the molecular mechanisms that underlie the SBRT DDR (7). The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. 1. Wachsberger PR, Lawrence RY, Liu Y, Rice B, Daskalakis C, Dicker AP. Epidermal growth factor receptor mutation status and rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation. Front Oncol (2013) 3:13. doi:10.3389/fonc.2013.00013 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar 2. Wright CM, Dan T, Dicker AP, Simone NL. microRNAs: the short link between cancer and RT-induced DNA damage response. Front Oncol (2014) 4:133. doi:10.3389/fonc.2014.00133 CrossRef Full Text | Google Scholar 3. Mladenov E, Magin S, Soni A, Iliakis G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol (2013) 3:113. doi:10.3389/fonc.2013.00113 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar 4. Braunstein S, Nakamura JL. Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk. Front Oncol (2013) 3:73. doi:10.3389/fonc.2013.00073 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar 5. Dasgupta T, Haas-Kogan DA. The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas. Front Oncol (2013) 3:110. doi:10.3389/fonc.2013.00110 CrossRef Full Text | Google Scholar 6. Rivera M, Sukhdeo K, Yu J. Ionizing radiation in glioblastoma initiating cells. Front Oncol (2013) 3:74. doi:10.3389/fonc.2013.00074 CrossRef Full Text | Google Scholar 7. Perez BA, Ghafoori AP, Lee CL, Johnston SM, Li Y, Moroshek JG, et al. Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice. Front Oncol (2013) 3:72. doi:10.3389/fonc.2013.00072 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text | Google Scholar Keywords: ionizing radiation, ionizing radiation induced DNA damage, DNA damage, radiation, editorial Citation: Haas-Kogan DA, Raleigh DR and Dicker AP (2014) Toward an improved understanding of the ionizing radiation induced DNA damage/response networks in human malignancies. Front. Oncol. 4:335. doi: 10.3389/fonc.2014.00335 Received: 31 October 2014; Accepted: 05 November 2014; Published online: 04 December 2014. Edited and reviewed by: Timothy James Kinsella, Warren Alpert Medical School of Brown University, USA Copyright: © 2014 Haas-Kogan, Raleigh and Dicker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: dhaaskogan@radonc.ucsf.edu; Adam.Dicker@jefferson.edu †All authors contributed equally to this Editorial.

  • Open Access

    Non-Muscle Myosin IIa Heavy Chain Links Squamous-Cell Carcinoma of the Head and Neck to the DNA Damage Response

    by David R. Raleigh, Daphne A. Haas-Kogan

    A commentary on Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas by Schramek D, Sendoel A, Segal JP, Beronja S, Heller E, Oristian D, Reva B, Fuchs E. Science (2014) 343:309–13. doi:10.1126/science.1248627 The incidence of squamous cell carcinoma of the head and neck (HNSCC) reaches as high as 16.5 cases per 100,000 individuals in the United States (1). Early-stage lesions have a favorable prognosis when treated surgically, but approximately two-thirds of HNSCC are diagnosed at an advanced locoregional stage (2). Chemoradiation is the backbone of treatment for the majority of advanced tumors, and is associated with up to 80% long-term survival for patients with positive prognostic features (3). Notably, the success of genotoxic therapy for advanced HNSCC far exceeds non-surgical control rates for the majority of epithelial tumors. Moreover, the primary benefit from chemotherapy for HNSCC is conferred not through a decrease in distant metastases but through enhanced local control (4, 5). As such, significant efforts have been dedicated to elucidating the molecular drivers of HNSCC genesis and identifying the pathways that sensitize these malignancies to the effects of chemoradiation. Infection with high-risk human papilloma virus (HPV) subtypes has emerged as an important risk factor for HNSCC. Unlike lesions associated with excessive tobacco and alcohol use, TP53 mutations are rarely found in HPV-positive HNSCC, which is generally associated with a favorable clinical course (6). Despite this association, no targeted therapies against HPV oncogenes are available for the treatment of patients with HNSCC. Similarly, genetic and epigenetic aberrations of the H-RAS, NOTCH, PI3K/Akt, BRCA1, and TGF-β pathways have also been associated with HNSCC, but targeted agents remain in preclinical stages for HNSCC (2). In contrast, epidermal growth factor receptor (EGFR) inhibition combined with radiotherapy is an effective strategy for HNSCC (7). EGFR is upregulated in approximately 90% of HNSCCs, and expression level is an independent determinant for decreased survival and impaired locoregional control (8, 9). However, EGFR inhibitors as monotherapy have produced only modest clinical outcomes, and survival from HNSCC has not improved in recent decades. Consequently, enhanced understanding of the molecular carcinogenesis of HNSCC is required to facilitate development of new treatments. Using an in vivo RNA interference (RNAi) strategy to screen for driver mutations involved in tumorigenesis, Schramek and colleagues recently reported a novel link between cutaneous squamous-cell carcinoma (CSCC), HNSCC, and impaired DNA damage response (DDR) signaling (10). To do so, a lentivirus-mediated RNAi library was selectively delivered to the surface ectoderm in utero under ultrasound guidance in a TGF-β-receptor-II conditional knockout murine model of CSSC and HNSCC. Selection of multiple independent small hairpin RNAs (shRNAs) in three or more tumors yielded eight potential tumor suppressors. Among these lesions, 40% were enriched with shRNAs against Myh9, which encodes non-muscle myosin IIa heavy chain. When conditionally suppressed in mice with endogenous TGF-β signaling, loss of myosin IIa was sufficient for development of CSCC, albeit with a significantly longer latency. By activating the DDR pathway, Schramek et al. further demonstrate that both myosin IIa suppression and small molecule inhibition delay and reduce p53 activation in response to double strand breaks. Consistently, loss of myosin IIa reduces the expression of p53-responsive genes, including p21, Fas, Bax, Mdm2, and 14-3-3σ. Finally, biochemical assays and microscopy both indicate that p53 fails to accumulate and/or remain in the nucleus in the absence of endogenous myosin IIa activity. These findings suggest a new role for myosin IIa as a tumor suppressor that facilitates the DDR through stabilization of p53 in the nucleus. Although the present data pertain to CSSC and HNSCC, it is intriguing to consider a broader role for myosin IIa in oncogenesis and the DDR. Also notable from this work is the non-invasive, ultrasound-guided method of selective shRNA delivery in utero. This novel technique circumvents the immunological and physiological confounders of orthotopic transplantation, and stands to have broad applications for future genetics screens. However, hairpin efficiency is a central component of RNAi and may bias data away from biological reality. Consistent with this limitation, TP53, which is frequently mutated in HNSCC, was not identified as a carcinogenic driver in the present study, presumably secondary to hairpin inefficiency. Despite the abundance of murine data presented by Schramek et al., the pathophysiological relevance of Myh9 loss for human malignancy remains uncertain. In this regard, approximately 80% of myosin IIa null HNSCCs in humans show concomitant loss of the TGF-β pathway, suggesting that myosin IIa loss may not be a direct oncogenic driver (10). Furthermore, a mere 30–40% of mice with intact TGF-β signaling develop tumors following Myh9 suppression and only do so after a mean latency of 1 year. Indeed, less than one-quarter of human SCCs and fewer than one-third of human HNSCCs show weak or absent immunolabeling for myosin IIa. Therefore, rather than functioning as a primary oncogenic driver in human malignancy, Myh9 mutation may play an accessory role in the genesis or progression of certain HNSCC subsets. In sum, it is likely that inactivating mutations of myosin IIa have a low penetrance in human HNSCC, as was suggested by the initial sequencing effort that identified a link between Myh9 and HNSCC (11). Nevertheless, these results provide compelling evidence that aberrant activity of the DDR is associated with HNSCC and further support the hypothesis that these tumors are both biologically and genetically diverse. Further studies are necessary to establish whether Myh9 mutation is of robust prognostic significance and if DDR pathways can be manipulated to enhance the efficacy of treatment for HNSCC. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. 1. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer (2013) 120(9):1290–314. doi:10.1002/cncr.28509 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 2. Leemans CR, Braakhuis BJM, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer (2011) 11:9–22. doi:10.1038/nrc2982-c2 CrossRef Full Text 3. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 363:24–35. doi:10.1056/NEJMoa0912217 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 4. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol (2003) 21:92–8. doi:10.1200/JCO.2003.01.008 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 5. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol (2004) 22:69–76. doi:10.1200/JCO.2004.08.021 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 6. Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst (2004) 96:998–1006. doi:10.1093/jnci/djh183 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 354:567–78. doi:10.1056/NEJMoa053422 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 8. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol (2006) 24:2666–72. doi:10.1200/JCO.2005.04.8306 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 9. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res (2002) 62:7350–6. Pubmed Abstract | Pubmed Full Text 10. Schramek D, Sendoel A, Segal JP, Beronja S, Heller E, Oristian D, et al. Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science (2014) 343:309–13. doi:10.1126/science.1248627 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text 11. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 333:1157–60. doi:10.1126/science.1208130 Pubmed Abstract | Pubmed Full Text | CrossRef Full Text Keyword: myosin IIa Citation: Raleigh DR and Haas-Kogan DA (2014) Non-muscle myosin IIa heavy chain links squamous-cell carcinoma of the head and neck to the DNA damage response. Front. Oncol. 4:228. doi: 10.3389/fonc.2014.00228 Received: 14 July 2014; Accepted: 07 August 2014; Published online: 25 August 2014. Edited by: Reviewed by: Copyright: © 2014 Raleigh and Haas-Kogan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: dhaaskogan@radonc.ucsf.edu


  • Likelihood of Bone Recurrence in Prior Sites of Metastasis in Patients With High-Risk Neuroblastoma

    by Alexei L. Polishchuk, Richard Li, Christine Hill-Kayser, Anthony Little, Randall A. Hawkins, Jeffrey Hamilton, Michael Lau, Hung Chi Tran, Caron Strahlendorf, Richard S. Lemons, et al.


  • Molecular Targets and Mechanisms of Radiosensitization Using DNA Damage Response Pathways

    by David R Raleigh, Daphne A Haas-Kogan

    The cellular reaction to genomic instability includes a network of signal transduction pathways collectively referred to as the DNA damage response (DDR). Activated by a variety of DNA lesions, the DDR orchestrates cell cycle arrest and DNA repair, and initiates apoptosis in instances where damage cannot be repaired. As such, disruption of the DDR increases the prevalence of DNA damage secondary to incomplete repair, and in doing so, enhances radiation-induced cytotoxicity. This article describes the molecular agents and their targets within DDR pathways that sensitize cells to radiation. Moreover, it reviews the therapeutic implications of these compounds, provides an overview of relevant clinical trials and offers a viewpoint on the evolution of the field in the years to come.


  • Open Access

    The Combination of Novel Targeted Molecular Agents and Radiation in the Treatment of Pediatric Gliomas

    by Tina Dasgupta, Daphne A. Haas-Kogan

    Brain tumors are the most common solid pediatric malignancy. For high-grade, recurrent, or refractory pediatric brain tumors, radiation therapy (XRT) is an integral treatment modality. In the era of personalized cancer therapy, molecularly targeted agents have been designed to inhibit pathways critical to tumorigenesis. Our evolving knowledge of genetic aberrations in pediatric gliomas is being exploited with the use of specific targeted inhibitors. These agents are additionally being combined with XRT to increase the efficacy and duration of local control. In this review, we discuss novel agents targeting three different pathways in gliomas, and their potential combination with XRT. BRAF is a serine/threonine kinase in the RAS/RAF/MAPK kinase pathway, which is integral to cellular division, survival, and metabolism. Two-thirds of pilocytic astrocytomas, a low-grade pediatric glioma, contain a translocation within the BRAF gene called KIAA1549:BRAF that causes an overactivation of the MEK/MAPK signaling cascade. In vitro and in vivo data support the use of MEK or mammalian target of rapamycin (mTOR) inhibitors in low-grade gliomas expressing this translocation. Additionally, 15–20% of high-grade pediatric gliomas express BRAF V600E, an activating mutation of the BRAF gene. Pre-clinical in vivo and in vitro data in BRAF V600E gliomas demonstrate dramatic cooperation between XRT and small molecule inhibitors of BRAF V600E. Another major signaling cascade that plays a role in pediatric glioma pathogenesis is the PI3-kinase (PI3K)/mTOR pathway, known to be upregulated in the majority of high- and low-grade pediatric gliomas. Dual PI3K/mTOR inhibitors are in clinical trials for adult high-grade gliomas and are poised to enter studies of pediatric tumors. Finally, many brain tumors express potent stimulators of angiogenesis that render them refractory to treatment. An analog of thalidomide, CC-5103 increases the secretion of critical cytokines of the tumor microenvironment, including IL-2, IFN-γ, TNF-α, and IL-10, and is currently being evaluated in clinical trials for the treatment of recurrent or refractory pediatric central nervous system tumors. In summary, several targeted inhibitors with radiation are currently under investigation in both translational bench research and early clinical trials. This review article summarizes the molecular rationale for, and the pre-clinical data supporting the combinations of these targeted agents with other anti-cancer agents and XRT in pediatric gliomas. In many cases, parallels are drawn to molecular mechanisms and targeted inhibitors of adult gliomas. We additionally discuss the potential mechanisms underlying the efficacy of these agents.


  • Open Access

    Hepatocellular carcinoma: natural history, current management, and emerging tools

    by Daphne Haas-Kogan, Christopher Tinkle

    Peer reviewed article authored by (Tinkle CL, Haas-Kogan D). Read article or submit your manuscript for publishing.


  • Open Access

    PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome

    by Sabine Mueller, Joanna Phillips, Arzu Onar-Thomas, Eloy Romero, Shichun Zheng, John K. Wiencke, Sean M. McBride, Cynthia Cowdrey, Michael D. Prados, William A. Weiss, et al.

    The signaling pathways that underlie the pathogenesis of pediatric gliomas are poorly understood. We characterized the PI3K/Akt/mTOR pathway in pediatric gliomas of all grades. Using immunohistochemistry, we assessed activation of the PI3K/Akt/mTOR pathway by evaluating the downstream signaling molecules phospho(p)-S6, phospho(p)-4BP1, and phospho(p)-PRAS40; PTEN; and PTEN promoter methylation, as well as the MIB labeling index. We correlated these findings with the clinical outcomes of 48 children with gliomas. Eighty percent of high-grade gliomas (12/15) showed activation of the PI3K/Akt/mTOR pathway based on p-S6 and p-4EBP1 expression. The majority of high-grade gliomas were negative for PTEN expression (10/15), and 50% had PTEN promoter methylation (grade III: 2/4; grade IV: 3/6). Low-grade gliomas demonstrated PI3K/Akt/mTOR pathway activation in 14/32 (43.8%) by p-S6 and 16/32 (50%) by p-4EBP1. Over 50% of grade I (6/11) and almost all grade II tumors (6/7) showed PTEN promoter methylation. Tumor grade correlated negatively with PTEN expression and positively with expression of p-S6 and p-4EBP1 (PTEN: P = .0025; pS6: P = .0075; p-4EBP1: P = .0066). There was a trend toward inverse correlation of methylation of the PTEN promoter with expression of PTEN protein (P= .0990) and direct correlation of expression of p-S6 and p-4EBP1 with poorer clinical outcome, as measured by progression-free survival (p-S6: P= .0874; p-4EBP1: P= .0475). Tumors with no PTEN expression had a higher MIB labeling index (P= .007). The majority of pediatric gliomas show activation of the PI3K/Akt/mTOR pathway, with methylation of the PTEN promoter occurring commonly in these tumors.


  • The superiority of conservative resection and adjuvant radiation for craniopharyngiomas

    by Adam Schoenfeld, Melike Pekmezci, Michael J. Barnes, Tarik Tihan, Nalin Gupta, Kathleen R. Lamborn, Anu Banerjee, Sabine Mueller, Susan Chang, Mitchel S. Berger, et al.

    The purpose of this study is to evaluate the roles of resection extent and adjuvant radiation in the treatment of craniopharyngiomas. We reviewed the records of 122 patients ages 11–52 years who received primary treatment for craniopharyngioma between 1980 and 2009 at the University of California, San Francisco (UCSF). Primary endpoints were progression free survival (PFS) and overall survival (OS). Secondary endpoints were development of panhypopituitarism, diabetes insipidus (DI), and visual field defects. Of 122 patients, 30 (24%) were treated with gross total resection (GTR) without radiation therapy (RT), 3 (3%) with GTR + RT, 41 (33.6%) with subtotal resection (STR) without RT, and 48 (39.3%) with STR + RT. Median age at diagnosis was 30 years, with 46 patients 18 years or younger. Median follow-up for all patients was 56.4 months (interquartile range 18.9–144.2 months) and 47 months (interquartile range 12.3–121.8 months) for the 60 patients without progression. Fifty six patients progressed, 10 have died, 6 without progression. Median PFS was 61.1 months for all patients. PFS rate at 2 years was 61.5% (95% CI: 52.1–70.9). OS rate at 10 years was 91.1% (95% CI 84.3–97.9). There was no significant difference in PFS and OS between patients treated with GTR vs. STR + XRT (PFS; p = 0.544, OS; p = 0.735), but STR alone resulted in significantly shortened PFS compared to STR + RT or GTR (p < 0.001 for both). STR was associated with significantly shortened OS compared to STR + RT (p = 0.050) and trended to shorter OS compared to GTR (p = 0.066). GTR was associated with significantly greater risk of developing DI (56.3 vs. 13.3% with STR + XRT, p < 0.001) and panhypopituitarism (54.8 vs. 26.7% with STR + XRT, p = 0.014). In conclusion, for patients with craniopharyngioma, STR + RT may provide superior clinical outcome, achieving better disease control than STR and limiting side effects associated with aggressive surgical resection.


  • Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy

    by Sunanda Pejavar, Mei-Yin Polley, Sarah Rosenberg-Wohl, Sravana Chennupati, Michael D. Prados, Mitchel S. Berger, Anuradha Banerjee, Nalin Gupta, Daphne Haas-Kogan

    Management of pediatric intracranial ependymomas poses a major challenge, and optimal treatment remains controversial. We sought to investigate the roles of surgery, radiation, and chemotherapy in a historical cohort. Thirty-nine children, age 21 or younger, with non-metastatic intracranial ependymomas were treated from 1972 to 2008. Median age was 8 years (range 0.2–19.1). Twenty-one patients (54%) underwent GTRs, and 18 (45%) underwent STRs. Twenty-six patients (67%) received upfront adjuvant RT (67%), and 14 (44%) received adjuvant chemotherapy. Twenty-four patients had disease recurrence and 12 died. Only one patient recurred after 5 years. Median PFS was 2.7 years and median OS was 20 years. Fifteen year PFS and OS were 30 and 67%. Adjuvant RT was associated with improved PFS (P = 0.045), and remained significant after adjusting for EOR (P = 0.04). Greater EOR trended towards prolonged survival, but did not reach statistical significance (P = 0.156). Of the patients that underwent GTR, the median PFS was 38 months for those treated with adjuvant RT versus 30 months for those that were not treated with RT. Of the patients that had STR, the median PFS for those treated with RT was 26.3 months versus 6.9 months for those were not treated with RT. In conclusion, for localized intracranial pediatric ependymomas, adjuvant RT is associated with improved PFS, even after adjusting for EOR. Our findings suggest the benefit of RT even in the presence of GTR. Future prospective studies with larger sample number are needed to validate our findings.